MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II

Clinical Epigenetics, Dec 2015

Background Pancreatic ductal adenocarcinoma (PDAC) remains a highly chemoresistant tumor entity for which no reliable molecular targets exist to predict or influence the success of chemotherapy. Recently, we identified a panel of microRNAs associated with induced gemcitabine chemoresistance in human PDAC cell lines. This clinical study evaluates these microRNAs and associated molecular markers as prognostic markers of outcome in 98 PDAC patients Union Internationale Contre le Cancer (UICC) stage II undergoing curative surgery with adjuvant gemcitabine chemotherapy. The primary end points of this study are recurrence-free survival and overall survival. Results Poor response to chemotherapy was significantly correlated to overexpression of microRNA-21 (p = 0.029), microRNA-99a (p = 0.037), microRNA-100 (p = 0.028), and microRNA-210 (p = 0.021) in tissue samples of PDAC patients UICC stage II. Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival (p < 0.05). Overexpression of phosphatase and tensin homolog (PTEN) (p = 0.039) and low expression of multidrug resistance (MDR)-1 (p = 0.043) and breast cancer resistance protein (BCRP)-1 (p = 0.038) were significantly correlated to improved response to adjuvant chemotherapy. Adjuvant gemcitabine treatment (p < 0.0001) and low tumor grading (p = 0.047) were correlated to better outcome. MicroRNA-100, microRNA-21, and its targets PTEN and MDR-1 were independent factors of survival in multivariate analysis. Conclusions Multivariate survival analyses identified microRNA-21 and microRNA-100 as unfavorable prognostic factors in resected and adjuvant treated PDAC UICC stage II patients.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1186%2Fs13148-015-0166-1.pdf

MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II

Dhayat et al. Clinical Epigenetics MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II Sameer Abdallah Dhayat 0 Baha Abdeen 0 Gabriele Köhler 2 Norbert Senninger 0 Jörg Haier 1 Wolf Arif Mardin 0 0 Department of General and Visceral Surgery, University Hospital Muenster , Albert-Schweitzer-Campus 1 (W1), 48149 Muenster , Germany 1 Comprehensive Cancer Center Muenster, University Hospital Muenster , Albert-Schweitzer-Campus 1 (W1), 48149 Muenster , Germany 2 Department of Pathology, University Hospital Muenster , Albert-Schweitzer-Campus 1 (D17), 48149 Muenster , Germany Background: Pancreatic ductal adenocarcinoma (PDAC) remains a highly chemoresistant tumor entity for which no reliable molecular targets exist to predict or influence the success of chemotherapy. Recently, we identified a panel of microRNAs associated with induced gemcitabine chemoresistance in human PDAC cell lines. This clinical study evaluates these microRNAs and associated molecular markers as prognostic markers of outcome in 98 PDAC patients Union Internationale Contre le Cancer (UICC) stage II undergoing curative surgery with adjuvant gemcitabine chemotherapy. The primary end points of this study are recurrence-free survival and overall survival. Results: Poor response to chemotherapy was significantly correlated to overexpression of microRNA-21 (p = 0.029), microRNA-99a (p = 0.037), microRNA-100 (p = 0.028), and microRNA-210 (p = 0.021) in tissue samples of PDAC patients UICC stage II. Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival (p < 0.05). Overexpression of phosphatase and tensin homolog (PTEN) (p = 0.039) and low expression of multidrug resistance (MDR)-1 (p = 0.043) and breast cancer resistance protein (BCRP)-1 (p = 0.038) were significantly correlated to improved response to adjuvant chemotherapy. Adjuvant gemcitabine treatment (p < 0.0001) and low tumor grading (p = 0.047) were correlated to better outcome. MicroRNA-100, microRNA-21, and its targets PTEN and MDR-1 were independent factors of survival in multivariate analysis. Conclusions: Multivariate survival analyses identified microRNA-21 and microRNA-100 as unfavorable prognostic factors in resected and adjuvant treated PDAC UICC stage II patients. Pancreatic ductal adenocarcinoma; Chemoresistance; microRNA Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly cancers in western countries with a median survival below 6 months and a dismal 5-year overall survival rate of less than 5 % [ 1 ]. Despite developments in novel diagnostic and surgical techniques over the past decades, only morbidity and postoperative mortality were improved, without significant impact on survival. Lack of early symptoms combined with rapid disease progression result in low resectability rates of about 15 % of PDAC patients with 5-year survival rates below 20 % [ 2 ]. Adjuvant first-line chemotherapy and palliative treatment by gemcitabine have slightly improved the clinical outcome. However, nearly half of the treated patients do not benefit from gemcitabine-based therapies [ 3, 4 ]. Chemotherapy response markers are needed to identify PDAC patients who may benefit from adjuvant gemcitabine chemotherapy. PDAC chemoresistance is acquired through multiple molecular pathways and genetic alterations affecting cell cycle, apoptosis, and intracellular drug accumulation. Especially, members of the ATP binding cassette (ABC) superfamily including multidrug resistance (MDR)-1 P-glycoprotein, multidrug resistance protein (MRP)-1, and breast cancer resistance protein (BCRP)-1 have been shown to mediate resistance against several anticancer drugs by enhanced drug efflux across cellular plasma membranes [ 5 ]. Deoxycytidine kinase (DCK), a key activator of gemcitabine, and its regulator Hu antigen R (HuR) have been identified as powerful independent prognostic factors for PDAC patients undergoing adjuvant gemcitabine therapy [ 6–8 ]. Further, mutations and epigenetic downregulation of phosphatase and tensin homolog (PTEN), a tumor suppressor and the most important negative regulator of Akt/PI3K signaling, are regarded as crucial for PDAC development and chemoresistance [ 9 ]. Although a number of molecular players have been connected to chemoresistance, their clinical impact remains controversial [ 10 ]. We previously identified a panel of microRNAs associated with induced gemcitabine chemoresistance in human PDAC cell lines: Two PDAC cell lines were treated by repeated pulsatile gemcitabine treatment to induce acquired chemoresistance. Global microRNA profiling identified a panel of 16 significantly and concordantly dysregulated microRNAs in both chemoresistant PDAC cell clones [ 11 ]. In this clinical study, our aim was to validate these microRNA candidates as prognostic markers of chemotherapy response to (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1186%2Fs13148-015-0166-1.pdf

Sameer Abdallah Dhayat, Baha Abdeen, Gabriele Köhler, Norbert Senninger, Jörg Haier, Wolf Arif Mardin. MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II, Clinical Epigenetics, 2015, pp. 132, Volume 7, Issue 1, DOI: 10.1186/s13148-015-0166-1